A database of FDA approved therapeutic peptides and proteins
| ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1627 | Th1138 | Raxibacumab | N.A. Full view | 0 | IIa | Immunological/Infectious | RAXIBACUMAB | GSK | Sterile, liquid formulation in single-dose vials | N.A. | Anti-Infective Agents and Monoclonal antibodies | Protective antigen |
| 1644 | Th1147 | Natalizumab | N.A. Full view | 0 | IIa | Genetic/Immunological | Tysabri | Biogen Idec Inc. | Sterile, colorless, and clear to slightly opalescent concentrate | Intravenous infusion | Immunosuppressive agents | N.A. |
| 1653 | Th1149 | Ragweed Pollen Extract | N.A. Full view | 0 | IIIa | Immunological | Ragwitek | Merck Sharp & Dohme | Tablets | Oral route | N.A. | N.A. |
| 1654 | Th1150 | Secukinumab | Secukinumab Heavy Ch Full view | 672 | IIa | Immunological | Cosentyx | Novartis Pharmaceuticals Corporation | Sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution. | Subcutaneous injection | Inhibitor | IL-17A cytokine |
| 1661 | Th1153 | Alefacept | Heavy Chain: CFSQQIY Full view | 705 | IIa | Immunological | Amevive | Astellas Pharma Inc. | Sterile, white-to-off-white, preservative-free, lyophilized powder | Intramuscular Injection | Dermatologic and Immunosupressive agents | T-cell surface antigen CD2, Complement C1r subcomponent, Complement C1q subcomponent subunit A, B, C, Low affinity immunoglobulin gamma Fc region receptor III-A,III-B, II-a, II-b, II-c |
| 1667 | Th1158 | Aprotinin | RPDFCLEPPYTGPCKARIIR Full view | 58 | IIa | Immunological | Trasylol | Bayer Pharmaceuticals | Clear, colorless, sterile isotonic solution | Intravenous administration | N.A. | Trypsin-1, Chymotrypsinogen B, Plasminogen, Kallikrein-! |
| 1772 | Th1187 | Human Rho(D) immune globulin | NA Full view | 0 | IIIb | Immunological Disorders | Hyp Rho D Inj 16.5% | Cutter Med & Biol, Division Of Miles Canada Ltd. | liquid | Intramuscular | NA | NA |
| 1773 | Th1187 | Human Rho(D) immune globulin | NA Full view | 0 | IIIb | Immunological Disorders | Hyperrho S/d Full Dose | GRIFOLS USA, LLC | Soution | Intramuscular | NA | NA |
| 1774 | Th1187 | Human Rho(D) immune globulin | NA Full view | 0 | IIIb | Immunological Disorders | Hyperrho S/d Mini-dose | GRIFOLS USA, LLC | Solution | Intramuscular | NA | NA |
| 1775 | Th1187 | Human Rho(D) immune globulin | NA Full view | 0 | IIIb | Immunological Disorders | Micrhogam Ultra-filtered Plus | Kedrion Melville, Inc. | Injection, Solution | Intramuscular | NA | NA |
| 1776 | Th1187 | Human Rho(D) immune globulin | NA Full view | 0 | IIIb | Immunological Disorders | Rhogam Ultra-filtered Plus | Kedrion Melville, Inc. | Injection, Solution | Intramuscular | NA | NA |
| 1777 | Th1187 | Human Rho(D) immune globulin | NA Full view | 0 | IIIb | Immunological Disorders | Rhophylac | Csl Behring Ag | Solution | Intramuscular; Intravenous | NA | NA |
| 1778 | Th1187 | Human Rho(D) immune globulin | NA Full view | 0 | IIIb | Immunological Disorders | Winrho Sdf | Aptevo Biotherapeutics Llc | kit | Intramuscular; Intravenous | NA | NA |
| 1779 | Th1187 | Human Rho(D) immune globulin | NA Full view | 0 | IIIb | Immunological Disorders | Winrho Sdf (liquid Formulation) | Aptevo Biotherapeutics Llc | liquid | Intramuscular; Intravenous | NA | NA |
| 1785 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Bivigam | Kedrion Biopharma, Inc. | Injection, Solution | Intravenous | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1786 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Bivigam | Biotest Pharmaceuticals Corporation | Injection, Solution | Intravenous | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1788 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Carimune Nanofiltered | Csl Behring Ag | Injection, Powder, Lyophilized, for Solution | Intravenous | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1791 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Flebogamma Dif | GRIFOLS USA, LLC | Injection, Solution | Intravenous | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1793 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Gamastan | Cutter Med & Biol, Division Of Miles Canada Ltd. | liquid | Intramuscular | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1794 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Gamastan S/d | GRIFOLS USA, LLC | Injection | Intramuscular | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1795 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Hyqvia | Baxalta Us Inc. | Liquid | Intravenous infusion | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1796 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Iveegam Immuno 5000mg (iv) | Baxter Ag | NA | NA | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1797 | Th1191 | Vedolizumab | Heavy Chain Sequence Full view | 716 | IIa | Immunological Disorders | Entyvio | Takeda Pharmaceuticals America, Inc. | Injection, Powder, Lyophilized, for Solution | Intravenous | Immunosupressive agent, Antineoplastic agent | Integrin alpha-4, Integrin beta-7 |
| 1802 | Th1196 | Siltuximab | Heavy Chain Sequence Full view | 708 | IIa | Immunological Disorders | Sylvant | Janssen Inc | Lyophilized Powder | Intravenous infusion | Antineoplastic and Immunomodulating Agents, Immunosuppressive Agents | Interleukin-6 |
| 1826 | Th1216 | Anthrax immune globulin human | NA Full view | 0 | IIa | Immunological Disorders | ANTHRASIL | Cangene Corporation | Liquid | Intravenous | Plasma derivative | Protective antigen |
| 1828 | Th1218 | Anti-thymocyte Globulin (Equine) | NA Full view | 0 | IIIb | Immunological Disorders | ATGAM | NA | Solid | Intravenous | Antibody | NA |
| 1829 | Th1219 | Anti-thymocyte Globulin (Rabbit) | NA Full view | 0 | IIIb | Immunological Disorders | ATG-Fresenius | Genzyme Inc. | Concentrate for solution for infusion. | Intravenous | Antibody | T-cell surface glycoprotein CD1a, Major histocompatibility complex class I-related gene protein, Integrin alpha-L, T-lymphocyte activation antigen CD86, Low affinity immunoglobulin gamma Fc region receptor II-b, T-cell surface glycoprotein CD4, Integrin beta-1, Integrin alpha-V, Integrin beta-3 |
| 1830 | Th1220 | Brodalumab | NA Full view | 0 | IIa | Immunological Disorders | Siliq | NA | sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution | Subcutaneous | Antineoplastic and Immunomodulating Agents | Interleukin 17 receptor A |
| 1832 | Th1222 | Canakinumab | H-GAMMA-1 Chain: QVQ Full view | 842 | IIa | Immunological Disorders | Ilaris | Novartis | Lyphilized powder | Subcutaneous | Antineoplastic and Immunomodulating Agents | Interleukin-1 beta |
| 1844 | Th1232 | Lenograstim | NA Full view | 0 | Ib | Immunological Disorders | Granocyte | NA | Solid | Subcutaneous or Intravenous | Antineoplastic and Immunomodulating Agents | Granulocyte colony-stimulating factor receptor |